Holen Sie sich die Stockscreener-App
94.05
2.83%
2.59
Handel nachbörslich:
94.00
-0.05
-0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.46
Offen:
$92.09
24-Stunden-Volumen:
1.29M
Relative Volume:
1.01
Marktkapitalisierung:
$10.92B
Einnahmen:
$2.77B
Nettoeinkommen (Verlust:
$286.61M
KGV:
40.02
EPS:
2.35
Netto-Cashflow:
$524.11M
1W Leistung:
+11.88%
1M Leistung:
+12.82%
6M Leistung:
-6.65%
1J Leistung:
-24.21%
1-Tages-Spanne:
$91.56
$94.92
1-Wochen-Bereich:
$83.30
$94.92
52-Wochen-Spanne:
$81.36
$129.50
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Vergleichen Sie RVTY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
94.05 | 10.62B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
543.32 | 198.23B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
214.99 | 150.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
631.19 | 50.71B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.64 | 39.32B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
206.63 | 34.74B | 15.70B | 1.24B | 2.01B | 6.9036 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Using AI based signals to follow Revvity Inc.Weekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
Can a trend reversal in Revvity Inc. lead to recoveryQuarterly Portfolio Report & Advanced Swing Trade Entry Plans - newser.com
Revvity to develop type 1 diabetes early detection assay with Sanofi - Investing.com Nigeria
Chart based analysis of Revvity Inc. trendsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Is Revvity Inc. stock undervalued vs historical averagesLong Setup & Accurate Entry/Exit Alerts - newser.com
Revvity Inc. stock trend outlook and recovery path2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - newser.com
Is Revvity Inc. stock a top pick for value investorsGlobal Markets & Weekly Momentum Stock Picks - newser.com
Automated trading signals detected on Revvity Inc.Trade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Order flow analysis tools used on Revvity Inc.July 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
Will Revvity Inc. (PKN) stock enhance shareholder valueDay Trade & Expert Approved Trade Ideas - newser.com
Lucem, Revvity partner with Sanofi for early T1D detection - BioWorld MedTech
Barclays Adjusts Revvity (RVTY) Price Target, Maintains Overweig - GuruFocus
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - PharmiWeb.com
Barclays Maintains Revvity (RVTY) Overweight Recommendation - Nasdaq
Revvity Expands Type 1 Diabetes Program With Sanofi Support - Nasdaq
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Ass - GuruFocus
Revvity Launches Program to Expand Type 1 Diabetes Diagnosis Offering - MarketScreener
Barclays Adjusts Price Target on Revvity to $100 From $110, Maintains Overweight Rating - MarketScreener
How Revvity Inc. (PKN) stock reacts to Fed tighteningJuly 2025 Breakouts & Free Reliable Trade Execution Plans - newser.com
Will Revvity Inc. stock sustain high P E ratiosJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
Bruker, Agilent, Revvity, Avantor, and Bio-Techne Shares Are Soaring, What You Need To Know - The Globe and Mail
Revvity Launches AI Software Transforming Preclinical Imaging - Precedence Research
How to recover losses in Revvity Inc. stockRate Cut & High Conviction Buy Zone Alerts - newser.com
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis - MarketScreener
Revvity (RVTY) Unveils Advanced AI Imaging Software for Researchers - GuruFocus
Revvity launches AI-powered multimodal analysis software for imaging research By Investing.com - Investing.com South Africa
Revvity launches AI-powered multimodal analysis software for imaging research - Investing.com
Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging Analysis - MarketScreener
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Yahoo Finance
Revvity Inc PKN Stock Analysis and ForecastMarket Sentiment Shifts & Affordable Portfolio Trading - earlytimes.in
Is Revvity Inc PKN a good long term investmentDouble Top/Bottom Patterns & High Return Portfolio Growth - earlytimes.in
What analysts say about Revvity Inc stockGlobal Trade Effects & Affordable Trading Strategies - earlytimes.in
Published on: 2025-09-27 18:11:56 - newser.com
Does AI Enzyme Partnership Mark a Turning Point for Revvity’s (RVTY) Clinical Growth Ambitions? - Sahm
What drives Revvity Inc PKN stock priceInstitutional Holding Changes & Small Budget Trading Portfolio - earlytimes.in
Revvity Stock: Is RVTY Underperforming the Healthcare Sector? - MSN
Revvity (RVTY) Receives a Buy from Bank of America Securities - The Globe and Mail
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Sys - PharmiWeb.com
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):